MX2019002269A - Anticuerpo monoclonal contra quinasa de cremallera de leucina embrionaria materna (melk) y utilizacion del mismo. - Google Patents

Anticuerpo monoclonal contra quinasa de cremallera de leucina embrionaria materna (melk) y utilizacion del mismo.

Info

Publication number
MX2019002269A
MX2019002269A MX2019002269A MX2019002269A MX2019002269A MX 2019002269 A MX2019002269 A MX 2019002269A MX 2019002269 A MX2019002269 A MX 2019002269A MX 2019002269 A MX2019002269 A MX 2019002269A MX 2019002269 A MX2019002269 A MX 2019002269A
Authority
MX
Mexico
Prior art keywords
melk
monoclonal antibody
antibody against
utilization
treatment
Prior art date
Application number
MX2019002269A
Other languages
English (en)
Inventor
Nakamura Yusuke
Harada Yosuke
Chung Suyoun
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2019002269A publication Critical patent/MX2019002269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales contra MELK. Además, la presente invención proporciona métodos para diagnosticar enfermedades asociadas con MELK utilizando los anticuerpos, métodos para detectar la proteína MELK, métodos para determinar la eficacia del fármaco después del tratamiento con un inhibidor de MELK, métodos de selección de sujetos en los que un inhibidor de MELK tiene un alto efecto terapéutico, y reactivos de diagnóstico que contienen los anticuerpos.
MX2019002269A 2016-08-31 2017-08-25 Anticuerpo monoclonal contra quinasa de cremallera de leucina embrionaria materna (melk) y utilizacion del mismo. MX2019002269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016169085 2016-08-31
PCT/JP2017/030443 WO2018043311A1 (ja) 2016-08-31 2017-08-25 Ｍｅｌｋに対するモノクローナル抗体およびその使用

Publications (1)

Publication Number Publication Date
MX2019002269A true MX2019002269A (es) 2019-09-18

Family

ID=61301839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002269A MX2019002269A (es) 2016-08-31 2017-08-25 Anticuerpo monoclonal contra quinasa de cremallera de leucina embrionaria materna (melk) y utilizacion del mismo.

Country Status (14)

Country Link
US (1) US11066477B2 (es)
EP (1) EP3508576A4 (es)
JP (1) JP7094557B2 (es)
KR (1) KR102579047B1 (es)
CN (1) CN109890963B (es)
AU (1) AU2017318907B2 (es)
BR (1) BR112019003408A2 (es)
CA (1) CA3035160A1 (es)
IL (1) IL264826B2 (es)
MX (1) MX2019002269A (es)
RU (1) RU2756982C2 (es)
SG (2) SG10202100683RA (es)
TW (1) TWI780067B (es)
WO (1) WO2018043311A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536247A (ja) * 2019-06-07 2022-08-15 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP5087059B2 (ja) 2001-10-31 2012-11-28 杏林製薬株式会社 ４−（２−メチル−１−イミダゾリル）−２，２−ジフェニルブタンアミドの製造方法
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1651956A4 (en) 2003-08-14 2008-08-20 Exelixis Inc MELKS AS MODIFIERS OF THE ACTION ACTION MECHANISM AND METHODS OF USE
JP4721903B2 (ja) 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
JP5028601B2 (ja) 2004-08-10 2012-09-19 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
AU2006315663A1 (en) 2005-11-10 2007-05-24 Exelixis, Inc. KIFS as modifiers of the RHO pathway and methods of use
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
WO2009131365A2 (ko) * 2008-04-21 2009-10-29 한국생명공학연구원 위암 진단 마커로서의 ｃst1, ｄcc1, ifitm1 또는 ｍelk
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
EP2574929A1 (en) * 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
EP2753329B1 (en) 2012-01-19 2017-08-09 OncoTherapy Science, Inc. 1,5-naphthyridine derivatives as melk inhibitors
RU2504785C1 (ru) 2012-11-23 2014-01-20 Общество с ограниченной ответственностью "Синтавр" Способ диагностики рака молочной железы
CN104995208A (zh) * 2013-01-11 2015-10-21 诺华股份有限公司 通过调节melk治疗乳腺癌
EP3239295A4 (en) 2014-12-12 2018-10-31 Kyoto University Antibody highly specifically recognizing turn structure at 22- and 23-positions in amyloid beta

Also Published As

Publication number Publication date
KR102579047B1 (ko) 2023-09-14
JPWO2018043311A1 (ja) 2019-06-24
JP7094557B2 (ja) 2022-07-04
EP3508576A1 (en) 2019-07-10
TWI780067B (zh) 2022-10-11
AU2017318907A2 (en) 2019-03-28
CA3035160A1 (en) 2018-03-08
EP3508576A4 (en) 2020-04-22
RU2756982C2 (ru) 2021-10-07
IL264826B2 (en) 2024-06-01
IL264826B1 (en) 2024-02-01
US11066477B2 (en) 2021-07-20
BR112019003408A2 (pt) 2019-06-25
US20190185575A1 (en) 2019-06-20
RU2019107355A3 (es) 2020-11-02
WO2018043311A1 (ja) 2018-03-08
SG10202100683RA (en) 2021-03-30
CN109890963B (zh) 2023-10-03
AU2017318907A1 (en) 2019-03-21
RU2019107355A (ru) 2020-10-01
TW201818972A (zh) 2018-06-01
AU2017318907B2 (en) 2023-07-06
KR20190043591A (ko) 2019-04-26
CN109890963A (zh) 2019-06-14
IL264826A (es) 2019-04-30
SG11201901435UA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
PH12019501146A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201790504A1 (ru) Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
NZ729773A (en) Biomarkers for disease progression in melanoma
MA55558A (fr) Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs
SG10201806729VA (en) Novel assay to detect human periostin
UY37082A (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv
MX2019002269A (es) Anticuerpo monoclonal contra quinasa de cremallera de leucina embrionaria materna (melk) y utilizacion del mismo.
MX2024009782A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
BR112019006422A2 (pt) anticorpo monoclonal contra fzd10 e utilização do mesmo
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
MX2017005650A (es) Composicion de antigeno para detectar enfermedad de chagas.
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus